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Abstract
Hemostasis is a defense mechanism to stop bleeding. Activated by vessel wall injury, it consists of
intertwined activation of platelets and the coagulation cascade, tightly controlled by natural
anticoagulants and the fibrinolytic system.
Introduction
Hemostasis is a defense mechanism to stop bleeding. Acti-
vated by vessel wall injury, it consists of intertwined acti-
vation of platelets and the coagulation cascade, tightly
controlled by natural anticoagulants and the fibrinolytic
system [1]. Inflammation aims at restorating the integrity
of damaged or threatened tissues, most frequently
because of injury or infectious pathogens. The coagula-
tion system and the innate inflammatory response share a
common ancestry and are coupled via common activation
pathways and feedback regulation systems. Primitive
organisms as the horseshoe crab have an integrated coag-
ulation and innate immune system [2]. More evolved spe-
cies have more complex and specialized systems, but a
two-way relationship between both has persisted
throughout evolution: coagulation triggers inflammatory
reactions and inflammation triggers the activation of the
coagulation system. Extensive cross-talk between inflam-
mation and coagulation involves cell receptor-mediated
signaling, cellular interactions and the production of cell-
derived microvesicles by endothelial cells, leukocytes and
platelets [3].
The role of platelets in (vascular) inflammation is illustra-
tive for this two-way relationship. After adhering to an
injured vessel wall, activated platelets release cytokines,
growth factors, and numerous proinflammatory media-
tors [4]. In addition, leukocytes are recruited to the site of
vascular damage via adhered platelet-leukocyte interac-
tions, mediated by P-selectin expressed on the activated
platelet surface and its counter-receptor on leukocytes, i.e.
P-selectin Glycoprotein Ligand-1 (PSGL-1) [5]. The same
ligand recruits circulating microvesicles from leukocytes
to the platelet surface [6], providing rapid intravascular
accumulation of microvesicular tissue factor (TF) that sus-
tains coagulation initially triggered by vascular TF. Plate-
lets also facilitate leukocyte recruitment to activated
endothelium by forming P-selectin-PSGL-1 mediated
conjugates with circulating leukocytes [7].
The many functions of TF and thrombin also are good
illustrations of the extensive cross-talking between inflam-
mation and coagulation. Inflammatory cytokines induce
TF expression in leukocytes and in endothelial cells. A
complex formation between TF and the coagulation factor
FVIIa or Xa is instrumental in initiating coagulation on
negatively-charged cell membranes, whereas membrane-
bound TF is also capable of signal transduction directly,
mediating inflammatory reactions [8]. Also, the major
coagulation enzyme thrombin has many functions
beyond haemostasis. It is a key regulator of cellular activa-
tion by activating PAR-receptors present on platelets but
also on endothelial cells, thus triggering inflammatory
pathways [9]. Of note, the generation of thrombin during
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hemostatic activation extends well beyond the moment at
which coagulation occurs, leaving room for thrombin-
mediated activity beyond hemostasis.
Fibrin also mediates cellular activation. It recruits and
activates platelets through the platelet receptor αIIbβ3, but
also leukocytes through interaction with the αMβ2 (mac-1)
integrin receptor [10]. Leukocyte binding to fibrin pro-
foundly alters leukocyte function, leading to phagocyto-
sis, NFκB-mediated transcription, production of
chemokines and cytokines and degranulation.
The two-way relationship between inflammation and
coagulation is apparent in the procoagulant pathways, but
also in the natural anticoagulant pathways that all have
been attributed anti-inflammatory properties. The three
major natural anticoagulants (Tissue Factor Pathway
Inhibitor (TFPI), Antithrombin (AT), Protein C/S) have
been investigated in clinical trials in patients with severe
sepsis, with varying success. The anti-inflammatory prop-
erties of thrombomodulin are increasingly recognized
[11]. Thrombin, bound to endothelial thrombomodulin,
activates Protein C, which together with its cofactor pro-
tein S decelerates the coagulation cascade by inactivating
factors Va and VIIIa. This ingenious mechanism also
exerts anti-inflammatory properties. Even when the
molecular dynamics of APC-mediated PAR-1 activation
are incompletely understood and subject to controversial
interpretation, the importance of the protein C system in
damping inflammation was confirmed in the PROWESS
trial [12]. In this randomized, controlled trial, the admin-
istration of recombinant human activated protein C
(drotrecogin-alfa) decreased mortality in patients with
severe sepsis, a condition characterized by massive activa-
tion of the coagulation system and vascular inflamma-
tion.
Endothelial cells integrate pro- and anticoagulant path-
ways but also pro- and anti-inflammatory stimuli.
Endothelial cells are actively involved in haemostasis,
limiting clot formation to sites of injury, but also localiz-
ing inflammatory processes to areas of damage, in part via
common pathways. Frequently used denominators as
endothelial "activation" or "stimulation" do not cover the
complexity of the endothelial cell response to different
physiological and pathological stimuli such as bacterial
invasion (sepsis, endocarditis) and exposure to toxins
(Shigella, uremic toxins), trauma (including lung transep-
ithelial passage of pollutants) or cytokines (tissue inflam-
mation, tumor burden). Inflammation shifts endothelial
cells towards a more prothrombotic state, downregulating
natural anticoagulant defense mechanisms and leading to
expression and de novo synthesis of prothrombogenic
molecules such as P-selectin, von Willebrand factor and
possibly also TF. Activated or apoptotic endothelial cells
may also release TF microvesicles which can contribute to
the pool of circulating microvesicular TF. Nonetheless, it
would be an oversimplification to state that in pathologi-
cal circumstances the endothelial cells change from an
anticoagulant, anti-inflammatory and vasodilatory phe-
notype to a procoagulant and proinflammatory state.
Coagulation and inflammation are closely linked, both in
health and disease. Indeed, failure of the complex balance
between pro- and anticoagulation, or between pro- and
anti-inflammatory reactions because of genetic or
acquired disturbances may result in disease. The many
links between inflammation and coagulation help explain
the prothrombotic tendency observed in patients with
acute inflammatory or infectious diseases. In addition,
chronic inflammatory diseases also predispose to venous
thrombosis but may also accelerate atherogenesis - a low-
grade vascular inflammatory disease. The endothelium
serves as the interface between inflammation and inap-
propriate activation of the coagulation system in diffuse
intravascular coagulation and thrombotic microangiopa-
thies. Polymorphisms may predispose to disease severity.
A common polymorphism in the PAI-1 gene has been
reported to affect the likelihood of patients with a menin-
gococcal infection to develop sepsis [13]. Mutations in
both complement factors as well as in thrombomodulin
have been linked to atypical hemolytic uremic syndrome
[9]. Factor XIIa, for a long time considered as an outsider
in the coagulation cascade, bridges the coagulation system
with the kallikrein-kininogen system and the complement
cascade, probably a remnant of the common ancestry of
the different systems. A gain of function mutation in fac-
tor XII has been linked to angio-oedema, similar to defi-
ciency in C1 esterase inhibitor. Many other disease-
modifying polymorphisms still need to be elucidated.
Pathogens have developed many strategies to counteract
the host defense system; some are of particular interest in
the perspective of the cross-talk between coagulation and
inflammation. The bacterial plasminogen activators are
well characterized: streptokinase from Streptococcus pyo-
genes, staphylokinase from Staphylococcus aureus and the
plasminogen activator Pla from Yersinia pestis proved piv-
otal for the spread of the bacteria in the host. The discov-
ery of streptokinase paved the way for the current
thrombolytic therapy. In order to enable feeding on mam-
mals, the leech hirudo medicinalis uses anticoagulants and
antiplatelet products to prevent clotting by the host. The
direct thrombin inhibitor lepirudin, has been derived
from the leech and was the first direct thrombin inhibitor
for clinical use.
Vascular biology has evolved as a research tool to help
explain a broad range of non-vascular diseases. Its role in
helping to unravel the pathophysiology of inflammatoryPublish with BioMed Central    and   every 
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and especially infectious diseases has just started. Under-
standing the molecular mechanisms of these diseases
offers the perspective for new therapies and enlarges the
research field for researchers in vascular biology, throm-
bosis and haemostasis.
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